ethyl 7-fluoroimidazo[1,2-a]pyridine-2-carboxylate | 1260798-14-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: ethyl 7-fluoroimidazo[1,2-a]pyridine-2-carboxylate
• 英文别名: Ethyl 7-fluoroimidazo[1,2-a]pyridine-2-carboxylate
• CAS: 1260798-14-8
• 化学式: C₁₀H₉FN₂O₂
• 分子量: 208.192
• InChiKey: JSAPJXGLIRVDFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 7-fluoroimidazo[1,2-a]pyridine-2-carboxylate 在 bis-triphenylphosphine-palladium(II) chloride 、 N-溴代丁二酰亚胺(NBS) 、 copper(l) iodide 、 lithium aluminium tetrahydride 、 氯化亚砜 、 四丁基氟化铵 、 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 3.5h， 生成
  参考文献：
  名称：

  Discovery of Imidazopyridine Derivatives as Highly Potent Respiratory Syncytial Virus Fusion Inhibitors

  摘要：

  A series of imidazolepyridine derivatives were designed and synthesized according to the established docking studies. The imidazopyridine derivatives were found to have good potency and physical-chemical properties. Several highly potent compounds such as 8ji, 8j1, and 8jm were identified with single nanomolar activities. The most potent compound 8jrn showed an IC50 of 3 nM, lower nnicrosome clearance and no CYP inhibition. The profile of 8jrn appeared to be superior to BMS433771, and supported further optimization.

  DOI：

  10.1021/acsmedchemlett.5b00008
• 作为产物：
  描述：

  2-氨基-4-氟吡啶 、 3-溴丙酮酸乙酯 以 乙二醇二甲醚 为溶剂， 以28 g的产率得到ethyl 7-fluoroimidazo[1,2-a]pyridine-2-carboxylate
  参考文献：
  名称：

  一种含氟咪唑并吡啶衍生物的制备方法

  摘要：

  本发明公开了一种咪唑并吡啶衍生物2‑(氯甲基)‑7‑氟‑咪唑并[1,2‑a]吡啶的制备方法，以2‑氨基‑4‑氟吡啶为起始原料，经过关环、还原、氯化得到目标产物，该化合物是重要的医药中间体。

  公开号：

  CN107286154A

文献信息

• Dibenzooxepin derivative
  申请人：Yamamoto Keisuke

  公开号：US08969345B2

  公开（公告）日：2015-03-03

  A dibenzoxepin derivative represented by the following general formula (I) wherein Y is a hydrogen atom and the like, RA is a hydrogen atom and the like, X is the formula (b3) wherein RB is a hydrogen atom and the like, and the like, A is the formula (a18) wherein R1 is a hydrogen atom and the like, and RC and RD are the same or different and each is a hydrogen atom and the like, and the like, which has a PPARγ agonist activity and the like, and useful as a therapeutic agent and/or prophylaxis agent and the like for type 2 diabetes and the like, or a pharmaceutically acceptable salt thereof and the like is provided.

  提供了一种二苯并氧吩衍生物，其通式表示为（I），其中Y为氢原子等，RA为氢原子等，X为式（b3），其中RB为氢原子等，A为式（a18），其中R1为氢原子等，RC和RD相同或不同，且每个为氢原子等，该物质具有PPARγ激动剂活性等，可用作治疗和/或预防2型糖尿病等的治疗剂和/或预防剂等，或其药学上可接受的盐等。
• DIBENZOOXEPIN DERIVATIVE
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2740730B1

  公开（公告）日：2016-11-16
• ANALOGUES OF CILOSTAZOL
  申请人：CONCERT PHARMACEUTICALS INC.

  公开号：US20130131021A1

  公开（公告）日：2013-05-23

  This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of a phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol.
• US8969345B2
  申请人：——

  公开号：US8969345B2

  公开（公告）日：2015-03-03